In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally Cagrilintide (10mg vials) Peptide Partners Beautyholic Meet Zephregine (Cagrilintide): The Next Generation Metabolic Peptide A breakthrough in weight management, designed to work with your body, not against it. BENEFITS Weight Loss & Body Composition Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide Advanced Research